Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Nick Bezuidenhout

  • Merck KGaA might jettison its biosimilar R&D program in the face of increasing competition
  • AstraZeneca will grant Sanofi access to its RSV program for the price of €120M
  • Actavis and Concordia are under scrutiny from a UK competition authority for ‘illegal’ deals

Sarine Arslanian

  • Merck KGaA presented positive Phase Ib results in psoriasis patients from a nanobody it picked up from Ablynx
  • Allergan received a green light to launch a new drug for night-time urination
  • Nicox resubmitted its NDA for reformulated Zyrtec, Zerviate

Forget the fox, what did the sloth say?


Images from Paul Strehlenert, Nick Bezuidenhout and Sarine Arslanian / shutterstock.com

ADVERTISEMENT
Previous post

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

Next post

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations